New Zealand markets close in 6 hours 26 minutes

REGN May 2024 740.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.5000-1.8000 (-41.86%)
As of 03:54PM EST. Market open.
Full screen
Previous close4.3000
Open4.3000
Bid0.1500
Ask4.5000
Strike740.00
Expiry date2024-05-17
Day's range2.5000 - 2.5000
Contract rangeN/A
Volume1
Open interest11
  • GlobeNewswire

    Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

    Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for Dupixent globally TARRYTOWN, N.Y. and PARIS, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent® (dupilumab) for the

  • Simply Wall St.

    Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock

    Many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders ditched their stock over the past year, which may be of...

  • Insider Monkey

    30 Most Valuable Drug Companies in 2024

    In this article, we will take a look at the 30 most valuable drug companies in 2024. If you want to skip our detailed analysis of the pharmaceutical drugs market, you can go directly to 5 Most Valuable Drug Companies in 2024. The Global Pharmaceutical Drugs Market According to a report by The Business Research […]